UK Markets close in 6 mins

Newron Pharmaceuticals S.p.A. (0QOI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
3.1000+0.0600 (+1.97%)
As of 03:05PM GMT. Market open.

Newron Pharmaceuticals S.p.A.

Via Antonio Meucci 3
Bresso, MI 20091
39 02 610 3461

Full-time employees25

Key executives

NameTitlePayExercisedYear born
Mr. Stefan WeberCEO & Exec. Director412.47kN/A1965
Mr. Roberto GalliVP of Fin.N/AN/AN/A
Mr. Marco CaremiExec. VP of Bus. Devel.N/AN/A1957
Dr. Ravi AnandChief Medical Officer1.01MN/A1957
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.


Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Corporate governance

Newron Pharmaceuticals S.p.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.